Zhavoronkov calls it a historic moment and credits Antonio Regalado of MIT Technology Review with breaking the news. The details of the data aren't given.
Recap by typeshit. Post by Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs) on X.
Among 208,970 matched adults with type 2 diabetes, GLP-1 starters had 0.15% new diagnoses versus 0.10% on DPP-4 drugs. Authors call it a signal needing confirmation.
Researchers used AI to identify fungal peptides that taste salty or boost saltiness, aimed at cutting sodium in food. A food science find rather than a drug story.
The 1,200-person trial starts next year with MIT and Pitt researchers, funded by a $13 million Arnold Ventures grant, and will also track housing and jobs.
Researchers found the peptide they built as a treatment already circulates in human blood, at lower levels in people with cognitive impairment.
Dissolving strips are showing up in the peptide market. The Bee asks the FDA and researchers whether they are safe and actually work.
Oral strips are showing up in the peptide market. The piece asks the FDA and researchers whether they are safe or actually work.
Loading…